Trump Administration Reclassifies Marijuana to Schedule III, Easing Research and Business Tax Burdens
Trump administration reclassified marijuana to Schedule III, facilitating medical research and allowing cannabis businesses federal tax deductions, without legalizing recreational use.
Overview
President Trump's administration reclassified marijuana from Schedule I to Schedule III, a move supported by the Justice Department, acknowledging its medical use and lower abuse potential.
This reclassification shifts marijuana from a category with dangerous drugs like heroin to one with substances such as Tylenol with codeine and ketamine, facilitating medical research.
Rescheduling allows marijuana businesses to claim standard federal income tax deductions for expenses, significantly benefiting their financial operations and easing tax burdens.
The executive order explicitly does not federally legalize recreational marijuana or alter existing criminal justice policies, despite widespread public support for broader legalization and use.
Amidst public support for legalization, this policy shift faces opposition from some Republican lawmakers citing health and safety concerns.
Analysis
Center-leaning sources cover the story neutrally, focusing on the factual details of Trump's executive order to reclassify marijuana. They present the policy change, its immediate implications for research and industry, and a balanced range of reactions from various stakeholders without employing loaded language or selective emphasis. The coverage consistently explains the order's scope and limitations.